Antigrowth effect of some inhibitors of polyamine synthesis on transplantable prostate cancer.
Inhibitors of polyamine synthesis were tested for therapeutic effectiveness on transplantable prostate cancer. Inhibition of either ornithine decarboxylase or S-adenosyl-L-methionine decarboxylase (AMDC) by alpha-difluormethylornithine (DFMO) or methylglyoxal-bis[guanylhydrazone] (MGBG), respectively, was associated with significant antitumor effect. The combination of DFMO with MGBG was not only more effective but no more toxic than MGBG alone. Combination of MGBG with 9-B-D-arabinofuranosyladenine, an indirect effector of SAMDC, failed to increase therapeutic effectiveness of MGBG.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004359:Drug Therapy, Combination; D000518:Eflornithine; D006146:Guanidines / Q000627:therapeutic use*; D008297:Male; D008935:Mitoguazone / Q000008:administration & dosage / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009952:Ornithine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011073:Polyamines / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D014740:Vidarabine / Q000008:administration & dosage
D006146:Guanidines; D011073:Polyamines; D009952:Ornithine; D014740:Vidarabine; D008935:Mitoguazone; D000518:Eflornithine